These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11058870)

  • 1. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas.
    Bortolotto S; Chiadò-Piat L; Cavalla P; Bosone I; Chiò A; Mauro A; Schiffer D
    Int J Cancer; 2000 Nov; 88(4):554-7. PubMed ID: 11058870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas.
    Burns KL; Ueki K; Jhung SL; Koh J; Louis DN
    J Neuropathol Exp Neurol; 1998 Feb; 57(2):122-30. PubMed ID: 9600204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
    Miettinen H; Kononen J; Sallinen P; Alho H; Helen P; Helin H; Kalimo H; Paljärvi L; Isola J; Haapasalo H
    J Neurooncol; 1999 Feb; 41(3):205-11. PubMed ID: 10359140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.
    Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E
    Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.
    Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M
    Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKN2A/p16 in ependymomas.
    Bortolotto S; Chiadò-Piat L; Cavalla P; Bosone I; Mauro A; Schiffer D
    J Neurooncol; 2001 Aug; 54(1):9-13. PubMed ID: 11763427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas.
    Pohl U; Cairncross JG; Louis DN
    Brain Pathol; 1999 Oct; 9(4):639-43. PubMed ID: 10517502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas.
    Michaud K; de Tayrac M; D'Astous M; Paquet C; Gould PV; Saikali S
    PLoS One; 2018; 13(2):e0193213. PubMed ID: 29489901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 expression in gliomas: Correlation with CDKN2A gene deletion/ p16 loss and MIB-1 proliferation index.
    Purkait S; Sharma V; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Sarkar C
    Neuropathology; 2015 Oct; 35(5):421-31. PubMed ID: 26096306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis.
    Kawaguchi K; Oda Y; Saito T; Yamamoto H; Tamiya S; Takahira T; Miyajima K; Iwamoto Y; Tsuneyoshi M
    J Pathol; 2003 Nov; 201(3):487-95. PubMed ID: 14595762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry.
    Purkait S; Jha P; Sharma MC; Suri V; Sharma M; Kale SS; Sarkar C
    Neuropathology; 2013 Aug; 33(4):405-12. PubMed ID: 23311918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent deletion and 5' CpG island methylation of the p16 gene in primary malignant lymphoma of the brain.
    Zhang SJ; Endo S; Ichikawa T; Washiyama K; Kumanishi T
    Cancer Res; 1998 Mar; 58(6):1231-7. PubMed ID: 9515810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes.
    Wolter M; Reifenberger J; Blaschke B; Ichimura K; Schmidt EE; Collins VP; Reifenberger G
    J Neuropathol Exp Neurol; 2001 Dec; 60(12):1170-80. PubMed ID: 11764089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome.
    Lim AM; Do H; Young RJ; Wong SQ; Angel C; Collins M; Takano EA; Corry J; Wiesenfeld D; Kleid S; Sigston E; Lyons B; Fox SB; Rischin D; Dobrovic A; Solomon B
    Int J Cancer; 2014 Aug; 135(4):887-95. PubMed ID: 24436120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
    Nielsen GP; Burns KL; Rosenberg AE; Louis DN
    Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5' CpG island methylation of p16 is associated with absence of p16 expression in glioblastomas.
    Park SH; Jung KC; Ro JY; Kang GH; Khang SK
    J Korean Med Sci; 2000 Oct; 15(5):555-9. PubMed ID: 11068994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas.
    Fueyo J; Gomez-Manzano C; Bruner JM; Saito Y; Zhang B; Zhang W; Levin VA; Yung WK; Kyritsis AP
    Oncogene; 1996 Oct; 13(8):1615-9. PubMed ID: 8895506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDKN2A promoter methylation in gastric adenocarcinomas: clinical variables.
    Vo QN; Geradts J; Boudreau DA; Bravo JC; Schneider BG
    Hum Pathol; 2002 Dec; 33(12):1200-4. PubMed ID: 12514789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
    Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
    Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma.
    Mohseny AB; Tieken C; van der Velden PA; Szuhai K; de Andrea C; Hogendoorn PC; Cleton-Jansen AM
    Genes Chromosomes Cancer; 2010 Dec; 49(12):1095-103. PubMed ID: 20737480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.